By Chris Wack
Esperion shares were up 13% to $3.16 after the company said it has filed New Drug Submissions to Health Canada for Nexletol and Nexlizet, non-statin medications that reduce low-density lipoprotein cholesterol and cardiovascular risk.
Shares of the Ann Arbor, Mich., company are up 120% in the past 12 months.
Nexletol and Nexlizet are indicated to reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy.
Nexlizet, alone or in combination with other LDL-C lowering therapies, will reduce LDL-C in adults with primary hyperlipidemia. Nexletol, in combination with other LDL-C lowering therapies, or alone when concomitant LDL-C lowering therapy isn't possible, will reduce LDL-C in adults with primary hyperlipidemia.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 02, 2024 11:05 ET (16:05 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.